Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ESRRA | P11474 | 6/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL481230 | 0.85 | ALDH1A1 (0.67) | ALDH1A1TSHRTTRLMNAFDPS | |
| SCHEMBL29953528 | 0.85 | ALDH1A1 (0.67) | ALDH1A1TSHRTTRLMNAFDPS | |
| SCHEMBL5606974 | 0.85 | AR (0.52) | ARALDH1A1TSHRTTRLMNA | |
| SCHEMBL16319639 | 0.85 | ALDH1A1 (0.51) | ALDH1A1TSHRTTRLMNAESRRA | |
| SCHEMBL2381821 | 0.81 | ESRRA (0.64) | ARALDH1A1TSHRTTRESRRA | |
| SCHEMBL2383238 | 0.81 | ESRRA (0.66) | ARALDH1A1TSHRTTRESRRA | |
| SCHEMBL28889415 | 0.81 | ESRRA (0.63) | ARALDH1A1TSHRTTRESRRA | |
| SCHEMBL29965683 | 0.81 | ESRRA (0.63) | ARALDH1A1TSHRTTRESRRA | |
| SCHEMBL5343920 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TSHRTTRESRRAFDPS | |
| SCHEMBL5142721 | 0.80 | AR (0.56) | ARALDH1A1ESRRAACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346549-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250084023-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2024-05-02 | — | — | US | disclosed |
| EP-1838300-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | Emergent Product Development Gaithersburg Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006071471-A2 | 2-(2 OR 4-SUBSTITUTED ARYLOXY)-PHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211697-A1 | 2-(2 Or 4-substituted aryloxy)-phenol derivatives as antibacterial agents | TYR, NFE2L2, CYP1A1 | AR 1336/4885ALDH1A1 1406/4885TSHR 2734/4885 |
| US-20250084023-A2 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | AR 64/4885ALDH1A1 810/4885TSHR 3720/4885 |
| US-20250346549-A2 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | AR 64/4885ALDH1A1 810/4885TSHR 3720/4885 |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | AR 64/4885ALDH1A1 810/4885TSHR 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.